Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
Melissa S BourqueMarta SalekNoah D SabinMeredith CanaleSanthosh A UpadhyayaPublished in: Pediatric blood & cancer (2020)